Melody Chang, R.Ph., says payers cover bispecific and CAR-T drugs but not the monitoring that lets community practices deliver them safely at lower cost.
|Podcasts|November 21, 2020
Meet the Board: HealthPartners' Kevin Ronneberg Talks Shift From In-Person to Remote Care in new Normal, HealthPartners and What he's Currently Reading
Author(s)Briana Contreras, Peter Wehrwein
This week on Tuning into the C-Suite, listeners are tuning into the next feature of the Meet the Board Series where Managed Healthcare Executive Senior Editor Peter Wehrwein and Associate Editor Briana Contreras speak with MHE’s Board Member Kevin Ronneberg, M.D. Kevin is vice president and associate medical director for health initiatives at HealthPartners, an integrated, nonprofit provider and health insurance company located in Bloomington, Minnesota. During the conversation we got to learn more about Kevin, personally, and how he and his family are doing during the pandemic and his thoughts of the current issues healthcare is facing today.
Advertisement
To listen to more episodes featured on Tuning Into The C-Suite, visit us on Spotify , Apple Podcasts and iHeartRadio .
Advertisement
Related to this article
Continuous glucose monitoring cut mean A1C from 8.8% to 7.2% over 26 weeks in adults with type 2 diabetes not on insulin, 0.9 points more than routine care in the CONNECT trial.
American Oncology Network’s Melody Chang, R.Ph., says 18% of its first 70 outpatient bispecific patients had CRS, all low grade with no hospitalizations.
A screening program in eight countries found early-stage type 1 diabetes in about 1 in 350 children with no family history of the disease.
Healthcare leaders should be preparing now for important changes in prior authorization and other areas of healthcare.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say staff-driven ideas protect research independence in industry partnerships.
UC Davis Health’s Tiffany Phung, Pharm.D., and Tim Cutler, Pharm.D., say research justifies services and opens doors to limited distribution drugs.
Garza, an expert on hidradenitis suppurativa at Johns Hopkins, says increasing incidence of the disease on the Japanese island of Okinawa offer some "tantalizing clues" about reasons for the rising incidence.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Apothecary Pharma recalls compounded tirzepatide and NAD+ vials over sterility concerns
2
Rex Hoffman, M.D., on how a CMO balances competing priorities | HSES 2026
3
Jessica Castle, M.D., discusses CGM’s A1C impact in non-insulin type 2 diabetes
4
Eric K. Singhi, M.D., on lung cancer among younger adults
5